AstraZeneca Reports Results of Tagrisso (osimertinib) in P-III ADAURA study for EGFR-Mutated Lung Cancer #ASCO20

Shots:

• The P-III ADAURA study involves assessing of Tagrisso (80 mg, qd) vs PBO in the adjuvant treatment of 682 patients with stage IB, II, and IIIA EGFRm NSCLC with complete tumor resection & adjuvant CT as an option across 20+ countries
• Results: in 1EPs of DFS & DFS in IIT population (83% & 79%) reduction in risk of disease recurrence or death, @2yrs. the patient remained alive & disease-free (89% vs 53%), presented at ASCO on May 31, 2020. Multiple presentations during ASCO20 showcased AstraZeneca’s leadership in lung cancer across early- and late-stage disease and reinforce the Company’s biomarker-driven approach
• Tagrisso (40 & 80mg) is a third-generation, irreversible EGFR-TKI with clinical activity against CNS metastases and has received approval as 1L treatment for EGFRm advanced NSCLC in many countries across the globe including US, EU, Japan, China

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca